Search

This letter presents a 28 GHz balun‐first low noise amplifier (LNA) featuring a wide dB‐linear variable gain range. The architecture of LNA includes three‐stage cascode amplifiers. An integrated balun at the input stage provides RF ESD protection and converts a single‐ended signal to a differential one (S‐to‐D). A transformer‐based dual‐resonant matching network is designed and analyzed to achieve wideband performance. To realize a continuous dB‐linear variable gain range and consistent input/output matching, gain control is implemented in the second stage using a 5‐bit digital‐to‐analog converter (DAC) for a 32 dB gain range. The DAC can generate a nonlinear analog voltage to control the gate of the common‐gate transistor in the second cascode stage, inversely compensating for the nonlinear gain variations of the cascode amplifier. The LNA is fabricated in 65‐nm CMOS process with a core size of 0.154 mm². Measurement results exhibit a maximum gain of 33.5 dB and a minimum noise figure (NF) of 3.65 dB with a 3‐dB bandwidth of 23–29.5 GHz. The measured variable gain range is approximately 32 dB across 32 different gain states, with a linear gain step of ~1 dB per state and an IP1dB ranging from −6.5 dBm to −35.25 dBm. The power consumption is 35.4–48 mW from a 1.2 V supply voltage. [ABSTRACT FROM AUTHOR]

Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disorder marked by immune system dysregulation and autoantibodies production, causing widespread inflammation and damage across various body systems. Despite the prevalent back pain in SLE patients, the link between SLE and intervertebral disc (IVD) degeneration, a primary contributor to back pain, remains inadequately understood. This study explored the impact of SLE on IVD degeneration using the MRL/lpr mouse model, which effectively replicates human SLE manifestations. Methods: The study utilized MRL/lpr mice to investigate the effects of SLE on IVD degeneration. The mice were evaluated for typical SLE phenotypes and indicators of IVD degeneration, including IVD height, IVD score, tissue integrity, extracellular matrix degradation, and apoptosis of IVD cells. Additionally, the study examined nucleus pulposus (NP) pyroptosis and inflammatory cytokine secretion. Mechanistic analysis focused on the antioxidant pathway, specifically the expression levels of NRF2, HO-1, KEAP1, and the phosphorylation levels of p65. Results: MRL/lpr mice displayed typical SLE phenotypes and exacerbated profiles of IVD degeneration, including reduced IVD height, lower IVD score, significant IVD tissue impairment, extracellular matrix degradation, and increased apoptosis of IVD cells. Notably, SLE stimulated NP pyroptosis and excessive secretion of inflammatory cytokines. Mechanistic analysis indicated that the progression of SLE impedes the antioxidant pathway by downregulating NRF2 and HO-1 expression, upregulating KEAP1, and enhancing phosphorylation levels of p65. Conclusion: Our findings highlight the mechanistic link between SLE and IVD degeneration, suggesting potential therapeutic targets for mitigating back pain in SLE patients. [ABSTRACT FROM AUTHOR]

Background: Periprosthetic bone loss is a well‐known phenomenon following total hip arthroplasty (THA). However, the choice of drugs for prevention remains controversial. Therefore, the aim of this study was to determine the best drug to treat periprosthetic bone loss by comparing changes in bone mineral density (BMD) at different times after THA. Methods: A comprehensive search of five databases and two clinical trial registration platforms was undertaken from their inception through to August 31, 2023 to identify eligible randomized controlled trials. A Bayesian network meta‐analysis (NMA) was carried out for calculating the standardized mean difference (SMD) and the surface under cumulative ranking curve (SUCRA) of the BMD in calcar (Gruen zone 7) at 6 months, 12 months, and 24 months and over. Results: Twenty‐nine trials involving 1427 patients and 10 different interventions were included. The results demonstrated that at 6 months, denosumab had the highest ranking (SUCRA = 0.90), followed by alendronate (SUCRA = 0.76), and zoledronate (SUCRA = 0.73). At 12 months, clodronate ranked highest (SUCRA = 0.96), followed by denosumab (SUCRA = 0.84) and teriparatide (SUCRA = 0.82). For interventions with a duration of 24 months and over, denosumab had the highest SUCRA value (SUCRA = 0.96), followed by raloxifene (SUCRA = 0.90) and zoledronate (SUCRA = 0.75). Conclusion: Investigating the existing body of evidence revealed that denosumab demonstrates potential as an intervention of superior efficacy at the three specifically examined time points. However, it remains crucial to conduct further research to confirm these findings and determine the most effective treatment strategy. [ABSTRACT FROM AUTHOR]

The performance of the oxygen reduction reaction (ORR) can be enhanced through the utilization of multi-heteroatom doped, porous, and layered electrocatalysts. Nitrogen-doped graphene-like porous carbon (Cu–Fe–CN) was synthesized via a simple and cost-effective NaCl template method using maltose, FeCl3·6H2O, and CuCl2·H2O as precursors. This material exhibits excellent electrocatalytic activity towards the ORR. During the electrocatalysis process, the maltose-derived graphene-like porous carbon possesses abundant pores that facilitate rapid mass and electron transfer. Additionally, the incorporation of polyatomic dopants and the construction of the porous carbon framework result in an abundance of active sites. The optimized Cu–Fe–CN electrocatalyst exhibited a more positive half-wave potential (E1/2 = 0.87 V) in alkaline media, surpassing that of the commercial Pt/C (E1/2 = 0.84 V), and demonstrated exceptional durability. The average discharge voltage of Al–air batteries with the Cu–Fe–CN catalyst is always higher than that of Al–air batteries with the commercial Pt/C catalyst, at the same current density. The present study showcases a convenient approach for fabricating porous low-metal catalysts for the ORR, highlighting their immense potential in ORR catalysis and aluminum–air batteries. [ABSTRACT FROM AUTHOR]

Objective: Total hip arthroplasty (THA) effectively treats end‐stage hemophilic hip arthropathy. Given hemophilia's unique characteristics, perioperative bleeding remains a significant risk for patients undergoing THA. Tranexamic acid (TXA), an efficient antifibrinolytic agent, may benefit the outcomes of THA for patients with hemophilia (PWH). This study aims to explore the clinical efficacy of intra‐articular injection of TXA in treating perioperative bleeding in PWH and assess its additional clinical benefits. Methods: The retrospective study comprised data of PWH who received THA from January 2015 to December 2021 in the research center. A total of 59 individuals were included in the study, divided into a TXA group (n = 31) and a non‐TXA group (n = 28). We compared various parameters, including total blood loss (TBL), visible blood loss (VBL), occult blood loss (OBL), intraoperative coagulation factor VIII (FVIII) consumption, perioperative total FVIII consumption, hemoglobin (HB), erythrocyte sedimentation rate (ESR), C‐reactive protein (CRP), length of hospital stay, hospitalization costs, length of surgery, total protein, activated partial thromboplastin time (APTT), D‐dimer, rate of joint swelling, hip joint range of motion (ROM), visual analogue scale (VAS), and Harris hip joint function scale (HHS) between the two groups. Follow‐up assessments were conducted for up to 24 months. A Student's t test was utilized for the statistical analysis. Results: This study demonstrated that intra‐articular TXA effectively reduced TBL (1248.19 ± 439.88 mL, p < 0.001), VBL (490.32 ± 344.34 mL, p = 0.003), and OBL (757.87 ± 381.48 mL, p = 0.004) in PWH who underwent THA. TXA demonstrated effectiveness in reducing VAS scores on POD1, POD7, and POD14 and joint swelling rates on POD1, POD7, POD14, and at discharge (p < 0.05). Additionally, the TXA group achieved higher HHS ratings at all follow‐up time points (p < 0.05), showing superior hip joint mobility, lower postoperative inflammation levels, reduced factor VIII consumption during surgery, and less postoperative nutritional loss. No statistically significant differences were observed between the two groups in terms of hospital stay, hospitalization costs, surgery duration, and coagulation indicators. Conclusion: Intra‐articular injection of TXA reduces perioperative bleeding in PWH undergoing THA while also improving joint mobility, post‐operative rehabilitation, and quality of life. This may provide value for the future application of TXA in PWH. [ABSTRACT FROM AUTHOR]